Patents by Inventor William G. Nelson
William G. Nelson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230405690Abstract: Various examples embodiments are directed to issues such as those addressed above and/or others which may become apparent from the following disclosure concerning the involving the attachment of a fixture to a vertical surface.Type: ApplicationFiled: June 15, 2023Publication date: December 21, 2023Inventor: William G. Nelson
-
Publication number: 20230100402Abstract: The disclosure generally relates to compositions and methods for the treatment of cancer. In some aspects, disclosed herein are methods for the induction of synthetic lethality with epigenetic therapy (ISLET) using a combination of at least one epigenetic compound and at least one chemotherapeutic agent. Also disclosed herein are screening methods for identifying compounds that induce killing of cancer cells when combined with at least one epigenetic compound. Further disclosed herein are methods of potentiating a therapeutic effect of a chemotherapeutic agent against a cancer, comprising administering to a subject having the cancer an epigenetic compound in an amount effective to potentiate the therapeutic effect of the chemotherapeutic agent against the cancer.Type: ApplicationFiled: September 16, 2022Publication date: March 30, 2023Inventors: Srinivasan Yegnasubramanian, William G. Nelson, Ajay Vaghasia, Philipp Nuhn
-
Publication number: 20230003718Abstract: Provided herein are methods for determining a rate of DNA double strand repair on a DNA strand in a cell that include (a) delivering a reporter gene, a gene-editing agent, and a gene-repair template into a cell, wherein the gene-editing agent generates a DNA double strand break on the DNA strand; (b) detecting a change in reporter gene expression, wherein the change in reporter gene expression indicates the presence of a DNA double strand repair event; and (c) analyzing the change in reporter gene expression, thereby determining the rate of DNA double strand repair on the DNA strand in the cell.Type: ApplicationFiled: June 21, 2022Publication date: January 5, 2023Inventors: Srinivasan Yegnasubramanian, Chaya Steinberg, William G. Nelson
-
Patent number: 11491174Abstract: The disclosure generally relates to compositions and methods for the treatment of cancer. In some aspects, disclosed herein are methods for the induction of synthetic lethality with epigenetic therapy (ISLET) using a combination of at least one epigenetic compound and at least one chemotherapeutic agent. Also disclosed herein are screening methods for identifying compounds that induce killing of cancer cells when combined with at least one epigenetic compound. Further disclosed herein are methods of potentiating a therapeutic effect of a chemotherapeutic agent against a cancer, comprising administering to a subject having the cancer an epigenetic compound in an amount effective to potentiate the therapeutic effect of the chemotherapeutic agent against the cancer.Type: GrantFiled: June 6, 2018Date of Patent: November 8, 2022Assignee: The Johns Hopkins UniversityInventors: Srinivasan Yegnasubramanian, William G. Nelson, Ajay Vaghasia, Philipp Nuhn
-
Publication number: 20220228969Abstract: An optical device includes a low-noise illumination source, a support device, an ultra low-noise detector, an analog-to-digital converter, and a controller. The low-noise illumination source is configured to generate a single beam of radiation. The support device is configured to support an object and to pass the single beam of radiation through the object. The object directly blocks, absorbs, or deflects portions of the single beam of radiation, thereby directly modulating the single beam of radiation. The low-noise detector is configured to detect the modulated single beam of radiation and to output an analog signal representative of vibrational spectra of the object. The modulated single beam of radiation is non-interferometric. The analog-to-digital converter is configured to convert the detected analog signal into a digital signal. The controller is configured to analyze and generate vibrational spectra of the object from the digital signal represented as a range of events over time.Type: ApplicationFiled: April 1, 2022Publication date: July 21, 2022Applicant: Digital Harmonic LLCInventors: Paul Reed SMITH, William G. NELSON, Shane G.W. MORRIS, Sandor SZALAY, Jonathan B. COULTER, Frederick M. SLAY, Eric K. PRITCHARD
-
Patent number: 11293853Abstract: Disclosed are systems and methods for measuring vibrational spectra of a living cells and tissue that includes a low noise consistent optical source creating a photon beam, a support device, a photon-to-electron converter/detector outputting a streamed analog electrical signal, an analog-to-digital converter, and a digital signal processor with specialized software for measuring and characterizing the signal contained in the photon beam and its subsequent detector's streamed analog converted to digital signal. Motion of the living sample causes modulation to the photon beam as it passes through the living samples by how much of the photon beam is blocked, absorbed or deflected. In addition, specific sub-cellular vibrational features can be segregated utilizing fluorescent markers.Type: GrantFiled: September 10, 2019Date of Patent: April 5, 2022Assignee: Digital Harmonic LLCInventors: Paul Reed Smith, William G. Nelson, Shane G. W. Morris, Sandor Szalay, Jonathan B. Coulter, Frederick M. Slay, Eric K. Pritchard
-
Publication number: 20210130879Abstract: BiSeqS (bisulfite sequencing system) is a technology that can increase the specificity of sequencing by at least two orders of magnitude over and above that achieved with molecular barcoding and can be applied to any massively parallel sequencing instrument. BiSeqS employs bisulfite treatment to distinguish the two strands of molecularly barcoded DNA. Its specificity arises from the requirement for the same mutation to be identified in both strands. Because no library preparation is required, the technology permits very efficient use of the template DNA as well as sequence reads, which are nearly all confined to the amplicons of interest. Such efficiency is critical for clinical samples, such as plasma, in which only tiny amounts of DNA are often available. BiSeqS can be applied to evaluate transversions, as well as small insertions or deletions, and can reliably detect one mutation among >10,000 wild type molecules.Type: ApplicationFiled: March 15, 2018Publication date: May 6, 2021Inventors: Bert VOGELSTEIN, Kenneth W. KINZLER, Nickolas PAPADOPOULOS, Austin MATTOX, Srinivasan YEGNASUBRAMANIAN, William G. NELSON
-
Publication number: 20210106603Abstract: The disclosure generally relates to compositions and methods for the treatment of cancer. In some aspects, disclosed herein are methods for the induction of synthetic lethality with epigenetic therapy (ISLET) using a combination of at least one epigenetic compound and at least one chemotherapeutic agent. Also disclosed herein are screening methods for identifying compounds that induce killing of cancer cells when combined with at least one epigenetic compound. Further disclosed herein are methods of potentiating a therapeutic effect of a chemotherapeutic agent against a cancer, comprising administering to a subject having the cancer an epigenetic compound in an amount effective to potentiate the therapeutic effect of the chemotherapeutic agent against the cancer.Type: ApplicationFiled: June 6, 2018Publication date: April 15, 2021Inventors: Srinivasan Yegnasubramanian, William G. Nelson, Ajay Vaghasia, Philipp Nuhn
-
Publication number: 20200149112Abstract: The present invention provides methods for discovering agents that are effective in reversing epigenetic silencing by inhibiting the interaction of methyl-binding (MBD) proteins with methylated genomic DNA. Also provided are methods for reactivating silenced genes having CpG island hypermethylation along with methods for treatment and prevention of diseases, such as cancer and sickle cell anemia, by administering an agent that modulates methyl-binding domain (MBD) protein-mediated transcriptional repression, thereby increasing gene transcription to prevent or treat disease. Additionally, compounds identified by the present invention useful for treatment and prevention of diseases, such as cancer and sickle cell anemia, are provided.Type: ApplicationFiled: February 25, 2019Publication date: May 14, 2020Inventors: William G. Nelson, Srinivasan Yegnasubramanian, Xiaohui Lin, Traci J. Speed, Zachery Reichert
-
Publication number: 20200064252Abstract: Disclosed are systems and methods for measuring vibrational spectra of a living cells and tissue that includes a low noise consistent optical source creating a photon beam, a support device, a photon-to-electron converter/detector outputting a streamed analog electrical signal, an analog-to-digital converter, and a digital signal processor with specialized software for measuring and characterizing the signal contained in the photon beam and its subsequent detector's streamed analog converted to digital signal. Motion of the living sample causes modulation to the photon beam as it passes through the living samples by how much of the photon beam is blocked, absorbed or deflected. In addition, specific sub-cellular vibrational features can be segregated utilizing fluorescent markers.Type: ApplicationFiled: September 10, 2019Publication date: February 27, 2020Applicant: Digital Harmonic LLCInventors: Paul Reed SMITH, William G. NELSON, Shane G.W. MORRIS, Sandor SZALAY, Jonathan B. COULTER, Frederick M. SLAY, Eric K. PRITCHARD
-
Publication number: 20190367990Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for assessing prostate cancer. In a specific embodiment, present inventors have developed and applied a new technology and associated computation methods enabling simultaneous genome-scale analysis of genetic (copy number) and epigenetic (total methylation (TM) and allele-specific methylation (ASM) alternation, This method, called MBD-SNP, features affinity enrichment or methylated genomic DNA fragments using a methyl-binding domain polypeptide.Type: ApplicationFiled: December 20, 2018Publication date: December 5, 2019Inventors: Srinivasan Yegnasubramanian, G. Steven Bova, Martin Aryee, William B. Isaacs, William G. Nelson
-
Patent number: 10227654Abstract: The present invention provides methods for discovering agents that are effective in reversing epigenetic silencing by inhibiting the interaction of methyl-binding (MBD) proteins with methylated genomic DNA. Also provided are methods for reactivating silenced genes having CpG island hypermethylation along with methods for treatment and prevention of diseases, such as cancer and sickle cell anemia, by administering an agent that modulates methyl-binding domain (MBD) protein-mediated transcriptional repression, thereby increasing gene transcription to prevent or treat disease. Additionally, compounds identified by the present invention useful for treatment and prevention of diseases, such as cancer and sickle cell anemia, are provided.Type: GrantFiled: May 8, 2015Date of Patent: March 12, 2019Assignee: The Johns Hopkins UniversityInventors: William G. Nelson, Srinivasan Yegnasubramanian, Xiaohui Lin, Traci J. Speed, Zachery Reichert
-
Patent number: 10196698Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for assessing prostate cancer. In a specific embodiment, present inventors have developed and applied a new technology and associated computation methods enabling simultaneous genome-scale analysis of genetic (copy number) and epigenetic (total methylation (TM) and allele-specific methylation (ASM) alternation, This method, called MBD-SNP, features affinity enrichment or methylated genomic DNA fragments using a methyl-binding domain polypeptide.Type: GrantFiled: May 18, 2017Date of Patent: February 5, 2019Assignee: The Johns Hopkins UniversityInventors: Srinivasan Yegnasubramanian, G. Steven Bova, Martin Aryee, William B. Isaacs, William G. Nelson
-
Publication number: 20180100196Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for assessing prostate cancer. In a specific embodiment, present inventors have developed and applied a new technology and associated computation methods enabling simultaneous genome-scale analysis of genetic (copy number) and epigenetic (total methylation (TM) and allele-specific methylation (ASM) alternation, This method, called MBD-SNP, features affinity enrichment or methylated genomic DNA fragments using a methyl-binding domain polypeptide.Type: ApplicationFiled: May 18, 2017Publication date: April 12, 2018Inventors: Srinivasan Yegnasubramanian, G. Steven Bova, Martin Aryee, William B. Isaacs, William G. Nelson
-
Publication number: 20160201966Abstract: An ice making machine includes a heat pipe that extends between a freezer compartment and a refrigerator compartment. The heat pipe has a first end in the freezer compartment and a second end in the refrigerator compartment. A heat exchanger is located in the freezer compartment and is in contact with the first end of the heat pipe. A heat block is located in the refrigerator compartment and is in contact with the second end of the heat pipe. A removable ice cube tray is mounted on the heat block with a surface in contact with the heat block such that when the removable ice cube tray is filled with water, ice forms from the surface of the removable ice cube tray in contact with the block.Type: ApplicationFiled: March 21, 2016Publication date: July 14, 2016Inventor: William G. Nelson
-
Patent number: 9297806Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for diagnosing or predicting cancer in a patient. In one embodiment, a method for identifying a patient as having cancer comprises the steps of (a) providing a formalin-fixed, paraffin-embedded or fresh frozen sample of patient tissue; (b) steaming the sample in antigen retrieval buffer; (c) incubating the sample in hydrochloric acid (HCl); (d) incubating the sample with an affinity reagent specific for 5hmC under conditions to form a complex between the affinity reagent and 5-hydroxymethylcytosine (5hmC) present in the sample; (e) detecting the complexes formed between 5hmC and the affinity reagent with secondary detection reagents; (f) quantifying 5hmC levels; and (g) identifying the patient as having cancer if the 5hmC levels in the sample are reduced as compared to a control.Type: GrantFiled: August 1, 2013Date of Patent: March 29, 2016Assignee: The Johns Hopkins UniversityInventors: Srinivasan Yegnasubramanian, Michael Christoph Haffner, Alcides Chaux, William G. Nelson, Angelo M. DeMarzo
-
Patent number: 9291381Abstract: An ice making machine includes a heat pipe that extends between a freezer compartment and a refrigerator compartment. The heat pipe has a first end in the freezer compartment and a second end in the refrigerator compartment. A heat exchanger is located in the freezer compartment and is in contact with the first end of the heat pipe. A heat block is located in the refrigerator compartment and is in contact with the second end of the heat pipe. A removable ice cube tray is mounted on the heat block with a surface in contact with the heat block such that when the removable ice cube tray is filled with water, ice forms from the surface of the removable ice cube tray in contact with the block.Type: GrantFiled: November 13, 2012Date of Patent: March 22, 2016Inventor: William G. Nelson
-
Patent number: 9034574Abstract: The present invention provides methods for discovering agents that are effective in reversing epigenetic silencing by inhibiting the interaction of methyl-binding (MBD) proteins with methylated genomic DNA. Also provided are methods for reactivating silenced genes having CpG island hypermethylation along with methods for treatment and prevention of diseases, such as cancer and sickle cell anemia, by administering an agent that modulates methyl-binding domain (MBD) protein-mediated transcriptional repression, thereby increasing gene transcription to prevent or treat disease. Additionally, compounds identified by the present invention useful for treatment and prevention of diseases, such as cancer and sickle cell anemia, are provided.Type: GrantFiled: December 21, 2007Date of Patent: May 19, 2015Assignee: The Johns Hopkins UniversityInventors: William G. Nelson, Srinivasan Yegnasubramanian, Xiaohui Lin, Traci J. Speed, Zachery Reichert
-
Publication number: 20140274767Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for assessing prostate cancer. In a specific embodiment, present inventors have developed and applied a new technology and associated computation methods enabling simultaneous genome-scale analysis of genetic (copy number) and epigenetic (total methylation (TM) and allele-specific methylation (ASM) alternation, This method, called MBD-SNP, features affinity enrichment or methylated genomic DNA fragments using a methyl-binding domain polypeptide.Type: ApplicationFiled: January 23, 2014Publication date: September 18, 2014Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Srinivasan Yegnasubramanian, G. Steven Bova, Martin Aryee, William B. Isaacs, William G. Nelson
-
Publication number: 20140038183Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for diagnosing or predicting cancer in a patient. In one embodiment, a method for identifying a patient as having cancer comprises the steps of (a) providing a formalin-fixed, paraffin-embedded or fresh frozen sample of patient tissue; (b) steaming the sample in antigen retrieval buffer; (c) incubating the sample in hydrochloric acid (HCl); (d) incubating the sample with an affinity reagent specific for 5hmC under conditions to form a complex between the affinity reagent and 5-hydroxymethylcytosine (5hmC) present in the sample; (e) detecting the complexes formed between 5hmC and the affinity reagent with secondary detection reagents; (f) quantifying 5hmC levels; and (g) identifying the patient as having cancer if the 5hmC levels in the sample are reduced as compared to a control.Type: ApplicationFiled: August 1, 2013Publication date: February 6, 2014Applicant: The Johns Hopkins UniversityInventors: Srinivasan Yegnasubramanian, Michael Christoph Haffner, Alcides Chaux, William G. Nelson, Angelo M. DeMarzo